In the absence of clear evidence, simply targeting the absence of seizures may minimize iatrogenic harm
PGI-C response of moderately improved or much improved. This group of patients, often refractory to treatment, had higher response rates with ritlecitinib than with placebo, although rates were lower than in patients without AT or AU.8 Patients with abnormal eyebrow or eyelash scores Among patients without normal eyebrow or eyelash assessment scores at baseline, improvement by 2 grades in eyebrow score or normalization of eyelash score increased over time across all four ritlecitinib groups (Fig
Pang Z, Chong J, Zhou G, de Lima Morais DA, Chang L, Barrette M
saline has no preservative
Kiehl KL, Curry WH, Stemper BD, et al